Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment

Abstract

The majority of cancer incidence and mortality occurs in individuals aged older than 65 years, and the number of older adults with cancer is projected to significantly increase secondary to the aging of the US population. As such, understanding the changes accompanying age in the context of the cancer patient is of critical importance. Agerelated changes can impact tolerance of anticancer therapy and can shift the overall risk-benefit ratio of such treatment. A challenge in implementing evidence-based approaches in older adults is the under-representation of this group in oncology clinical trials. In addition, although older adults are particularly vulnerable to the side effects of cancer therapy, few oncology studies to date have incorporated a measure of health status other than the Eastern Cooperative Oncology Group or Karnofsky performance scales. Novel metrics such as frailty indices or the geriatric assessment recognize heterogeneity among older adults, and may allow for risk-adapted approaches to therapy. It is increasingly recognized that several laboratory markers may predict morbidity and mortality in older adults; these biologic variables may further aid in stratifying this group of patients based on risk. This review describes key studies from the geriatric literature that provide principles for assessing health status in the older patient, and ways that these principles can be applied to oncology care in an older population are proposed. CA Cancer J Clin 2010;60:120-132.

Inpatient oncology rehabilitation in Toronto: a descriptive 18-month retrospective record review

“…Regression analysis revealed that function scores were likely to be lower for older patients. This is contradictory to findings by Van Cleave and colleagues, who investigated only those aged 65 or more and did not find an association between chronological age and functional status [25]. They did, however, find that an increased number of comorbidities were associated with reduced functional status.…”

Aging and cancer: can mTOR inhibitors kill two birds with one drug?

“…If the projections in population shifts prove correct and no mitigating interventions are developed, these numbers are just going to get worse. Compounding these issues is a shift in the risk-benefit ratio of anticancer therapeutics due to age-related changes that impact their tolerance [7]. Added to that is an underrepresentation of this demographic in clinical trials designed to evaluate potential therapies [7].…”

“…Compounding these issues is a shift in the risk-benefit ratio of anticancer therapeutics due to age-related changes that impact their tolerance [7]. Added to that is an underrepresentation of this demographic in clinical trials designed to evaluate potential therapies [7]. A central question is whether or not slowing the process of aging in human populations a) prevents and/or delays the development, growth and/or progression of cancer; b) improves patient's tolerance for anticancer therapeutics.…”

Characteristics of Frail Patients in a Geriatric-HIV Program: The Experience of an Urban Academic Center at One Year Follow-Up

“…Polypharmacy is a significant risk factor for functional deterioration and poor outcomes in elderly patients and a risk factor for increased morbidity and mortality. 14 Vitamin D deficiency has been associated with frailty syndrome. A study of 444 male and 561 female participants aged 65 years and older from the Inchanti study Shardell et al 15 found that vitamin D insufficiency was associated with frailty only in men.…”